HOME >> MEDICINE >> NEWS
12-month study demonstrated tolerability and efficacy of Daytrana

SAN DIEGO MAY 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that DAYTRANATM (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association (APA) annual meeting in San Diego.

"We documented that children with ADHD experienced effective ADHD treatment with use of DAYTRANA for 12 months, sustaining the improvements in their ability to maintain focus and concentration," said investigator Oscar Bukstein, M.D., M.P.H ,Associate Professor of Psychiatry, University of Pittsburgh School of Medicine. "More importantly, Daytrana maintained a favorable safety profile, meeting the study's primary endpoint, and demonstrating an incidence of adverse events that is consistent with previous trials and other stimulants in this class."

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. DAYTRANA is available in four dosage strengths 10 mg, 15 mg, 20 mg and 30 mg all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects.

Bukstein added, "DAYTRANA's novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their children's changing schedules."

This study was an open-label extension of four clinical trials. T
'"/>

Contact: Marion E. Glick
212-601-8273
Porter Novelli
23-May-2007


Page: 1 2 3

Related medicine news :

1. $1.5 billion needed to ensure 12-month stockpile of pediatric vaccines
2. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
3. Penn study finds pro-death proteins required to regulate healthy immune function
4. New study shows promise in reducing surgical risks associated with surgical bleeding
5. New study counts the economic cost of persistent pain in Australia
6. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
7. Most seniors now have drug coverage, U-M study shows
8. To gain muscle and lose fat, drink milk: study
9. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
10. Even older women at high risk have little interest in being tested for HIV, study finds
11. Metabolic study in mice could lead to good cholesterol boosters

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: month study demonstrated tolerability and efficacy Daytrana

(Date:5/23/2015)... (PRWEB) May 23, 2015 Javon ... at the Sports Medicine and Rehabilitation Center, 557 N. ... program, Mondays, June 1-July 20, 5:30-6:30 pm. , The ... coach, and Laurie Finke, RN, BSN, who will offer ... education on nutrition, running mechanics and show selection and ...
(Date:5/22/2015)... The world is at a "hinge ... to create new opportunities for leadership in health ... WesternU's 34th annual Commencement Exercises said Wednesday, May ... former San Francisco mayor and likely 2018 gubernatorial ... ceremony for WesternU's colleges of Allied Health Professions ...
(Date:5/22/2015)... Mountain Point Medical Center, a campus of Jordan Valley ... May 29, 2015 at 11 a.m., followed by a community ... center, set to officially open on June 1, 2015, is ... , “The opening of Mountain Point Medical Center is an ... said Kent Loosle, CEO of Mountain Point Medical Center. “Mountain ...
(Date:5/22/2015)... May 22, 2015 Following yesterday’s announcement ... agreement with US-based health brand Nature’s Way, Marc St-Onge ... Retention of Ascenta Skin is an integral part of ... about this opportunity to further develop Ascenta Skin into ... Ascenta Skin is a breakthrough, anti-aging skincare supplement featuring ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Hands ... that June 17, 2015, the Annual One Day Sale ... Since 2007, Hands On HCMT offers drastically reduced certificates one ... and estheticians have enough sessions, through what used to be ... is wonderful for the community as well. This once a ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
Cached News: